ACTB and neoplasm: When signatures from plasma- and ascites-derived sEVs were compared we found significant differences in expression of COL5A1, AEBP1, TIMP3, and ACTB at week 3 of tumor progression (Figure 6), suggesting that ascites-derived sEVs are likely a stronger indicator of tumor presence compared to plasma-derived sEVs.